| Q53174548 | B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). |
| Q39324849 | ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia |
| Q53235861 | Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. |
| Q36838768 | FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma |
| Q34355722 | Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis |
| Q38345572 | Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies. |
| Q37068011 | Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma |
| Q90125894 | Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies |
| Q36699109 | Molecular imaging of brain tumors: a bridge between clinical and molecular medicine? |
| Q41820676 | Molecular imaging of stem cell therapy in brain tumors: a step towards personalized medicine |
| Q36927213 | Overview of early response assessment in lymphoma with FDG-PET. |
| Q36746441 | PET and PET/CT for response evaluation in lymphoma: current practice and developments |
| Q37810092 | PET imaging in lymphoma |
| Q35650641 | PET in lymphoma |
| Q36963748 | PET/CT in oncology: for which tumours is it the reference standard? |
| Q37088536 | PET/CT in the management of haematological malignancies |
| Q37129821 | Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma |
| Q46656078 | Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. |
| Q36695611 | Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients |
| Q43173266 | Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation |
| Q83979145 | Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation |
| Q33622514 | Stem cell transplantation in brain tumors: a new field for molecular imaging? |
| Q80595793 | The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation |
| Q46165774 | The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. |
| Q37824456 | The role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings |
| Q53108799 | The role of ¹⁸F-fluorodeoxyglucose positron emission tomography at response assessment after autologous stem cell transplantation in T-cell non-Hodgkin's lymphoma patients. |
| Q37591299 | Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials |